Clinical Trial Update: Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

View source ↗

Summary

Expanded access program for Ulixertinib (BVD-523) in patients with advanced MAPK pathway-altered malignancies across multiple tumor types. The program is listed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Colorectal Cancer
• Head and Neck Cancer
• Melanoma
• Non-small Cell Lung Cancer
• Pancreatic Cancer
• Small Bowel Cancer
• Thyroid Cancer

Drugs mentioned

• Ulixertinib (ulixertinib)

Snippet

Sponsor: xCures | Conditions: Pancreatic Cancer, Small Bowel Cancer | Status: AVAILABLE